Insider · CIK 0001843601
Sandip I Patel
Files at AKTX (Akari Therapeutics Plc), PKBO (Peak Bio, Inc.), ATCH (AtlasClear Holdings, Inc.). First filing Sep 28, 2026, latest Sep 28, 2026.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ATCH: AtlasClear Holdings, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 40Moderate | AtlasClear Holdings, Inc. | $21k 100,000 shares | +12% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | ATCH AtlasClear Holdings, Inc. | AGrant or award Stock Option (right to buy)derivative | +777,332 | $0.00 | $0 | 777,332 | 10 d ago |
| Sep 24, 2026 | ATCH AtlasClear Holdings, Inc. | AGrant or award Common Stock | +50,000 | $0.22 | $11k | 855,130 | 14 d ago |
| Sep 24, 2026 | ATCH AtlasClear Holdings, Inc. | POpen-market purchase Common Stock | +50,000 | $0.22 | $11k | 855,130 | 14 d ago |
| Sep 25, 2026 | ATCH AtlasClear Holdings, Inc. | AGrant or award Common Stock | +50,000 | $0.20 | $9,875 | 905,130 | 14 d ago |
| Sep 25, 2026 | ATCH AtlasClear Holdings, Inc. | POpen-market purchase Common Stock | +50,000 | $0.20 | $9,875 | 905,130 | 14 d ago |
| Dec 16, 2025 | AKTX Akari Therapeutics Plc | POpen-market purchase Warrants to purchase American Depositary Shares ("ADRs")derivative | +247,462 | - | - | 247,462 | Dec 18, 2025 |
| Dec 16, 2025 | AKTX Akari Therapeutics Plc | POpen-market purchase Pre-Funded Warrants to purchase ADRsderivative | +247,462 | $0.40 | $100k | 247,462 | Dec 18, 2025 |
| Dec 16, 2025 | AKTX Akari Therapeutics Plc | POpen-market purchase Warrants to purchase ADRsderivative | +154,664 | - | - | 154,664 | Dec 18, 2025 |
| Dec 16, 2025 | AKTX Akari Therapeutics Plc | POpen-market purchase Pre-Funded Warrants to purchase ADRsderivative | +154,664 | $0.40 | $62k | 154,664 | Dec 18, 2025 |
| Mar 6, 2025 | AKTX Akari Therapeutics Plc | AGrant or award American Depositary Shares representing Ordinary Shares | +44,642 | $1.12 | $50k | 496,499 | Apr 29, 2025 |
| Mar 6, 2025 | AKTX Akari Therapeutics Plc | AGrant or award Series A Warrants (Right to Buy)derivative | +44,642 | $1.12 | $50k | 44,642 | Apr 29, 2025 |
| Mar 6, 2025 | AKTX Akari Therapeutics Plc | AGrant or award Series B Warrants (Right to Buy)derivative | +44,642 | $1.12 | $50k | 44,642 | Apr 29, 2025 |
| Mar 20, 2025 | AKTX Akari Therapeutics Plc | AGrant or award Stock Option (Right to Buy)derivative | +175,000 | $0.00 | $0 | 175,000 | Mar 24, 2025 |
| Mar 20, 2025 | AKTX Akari Therapeutics Plc | AGrant or award Stock Option (Right to Buy)derivative | +225,000 | $0.00 | $0 | 225,000 | Mar 24, 2025 |
| Nov 14, 2024 | PKBO Peak Bio, Inc. | CConversion Common Stock | +763,316 | - | - | 763,316 | Nov 18, 2024 |
| Nov 14, 2024 | PKBO Peak Bio, Inc. | DDisposition to issuer Common Stock | -763,316 | - | - | 0 | Nov 18, 2024 |
| Nov 14, 2024 | PKBO Peak Bio, Inc. | DDisposition to issuer Common Stockindirect: See footnote | -67,735 | - | - | 0 | Nov 18, 2024 |
| Nov 14, 2024 | PKBO Peak Bio, Inc. | DDisposition to issuer Common Stockindirect: See footnote | -68,891 | - | - | 0 | Nov 18, 2024 |
| Nov 14, 2024 | PKBO Peak Bio, Inc. | DDisposition to issuer Common Stockindirect: See footnote | -47,364 | - | - | 0 | Nov 18, 2024 |
| Nov 14, 2024 | PKBO Peak Bio, Inc. | CConversion Convertible Notesderivative | - | - | - | 0 | Nov 18, 2024 |
| Nov 14, 2024 | PKBO Peak Bio, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -400,000 | $0.00 | $0 | 0 | Nov 18, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.